English (UK)
中文版shuyuan PAN
our business covers R&D，manufacturing, logistics and distribution of medicinal products.
sinopharm
associate director（R&D managing department）Mr. Zongde Pan
Enbao asset
Investment anlystMr. Norberto Pandolfi Orecchia
We are a specialized company in high quality furniture of Investigational Medicinal Product (IMP) and in services for international clinics experimentations , our service has high flexibility in managing clinical trials from phase I to phase IV according to customers’ specific requirements.
Petrone Group Asia Pacific Pte Ltd
Managing DirectorMr. Raffaello Paolini
Regulaxis SAS is a French biotech company created in 2013 to develop innovative therapies for human clinic based on new synthetic peptides regulating cell growth and differentiation.
Regulaxis is specialized in the regulation of cell proliferation and/or cell differentiation. The potential therapeutic applications covered by our patents are very broad, especially in the areas of joint/bone or nerve cell regeneration, but also in cancer and related metabolic diseases (diabetes, obesity …).
Our mission is to grant licenses of innovative molecules in a pharmaceutical company after completion of phase II clinical proof of concept.
Regulaxis is strategically focused only on high unmet medical needs but has elected as its first priority:
regeneration of articular cartilage using intra-articular injections of its lead candidate REG-O3.
Regulaxis SAS
R&D Project Manager – East Asian operations developmentAshutosh Parihar
We at Singh Biotechnology (SBT) are interested in meeting with you to exploring possible opportunities for partnering/in-licensing/scientific collaboration.
SBT is a start-up biotech company established in 2014. We discover/develop unique and proprietary therapeutic single domain antibodies (sdAbs) for the treatment of a variety of cancers, autoimmune, ophthalmological, and viral diseases by leveraging our propriety novel technology platform. Using this technology platform SBT has been able to generate therapeutic sdAbs that specifically target intracellular molecules of interest that play an important role in the pathogenesis of disease(s). Our lead therapeutic (SBT-100) is a bi-specific sdAbs that specifically targets and inhibits intracellular KRAS and signal transducer and activator of transcription 3 (STAT3) proteins.
Singh Biotechnology
Vice PresidentYong H. Park
- Focused on developing PD1+ peripheral blood-derived, tumor-reactive CD8+ T cell (PBTL) therapies as a platform for the treatment of solid tumors that are rare, orphan, and have critical (high) unmet need
- PBTL is a simpler, smarter version of TIL
- PBTL is a process to select highly tumor-reactive T cells from a patient's peripheral blood based on the expression of two specific T cell surface markers: PD-1 and/or TIM-3
- After selection, expanded to large quantities, it gets re-infused into the patient via the ACT regimen
- PBTL technology has been patented (issued) already in the US, China, the EU, Japan, Australia
- MEDGENE has robust Clinical Development Pipelines (currently, 9 as monotherapy way)
- Looking for funding for entering Phase I/2 in three pipelines in the US
- Looking for partnering for the Asian market (China, Japan, South Korea)
Responsive Web Design powered by 